Product Information
69001-1-Ig targets NeutraKine® IL-6 in IF, Neutralization, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human, rat |
| Host / Isotype | Mouse / IgG1 |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen |
Recombinant Protein Predict reactive species |
| Full Name | interleukin 6 (interferon, beta 2) |
| Gene Symbol | IL6 |
| Gene ID (NCBI) | 3569 |
| ENSEMBL Gene ID | ENSG00000136244 |
| RRID | AB_2882919 |
| Conjugate | Unconjugated |
| Form | Lyophilized Powder |
| Purification Method | Protein A purification |
| UNIPROT ID | P05231 |
| Storage Buffer | Sterile PBS, pH 7.4. |
| Endotoxin | <0.1 EU/μg |
| Reconstitution | This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use. |
| Stability and Storage | Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products. |
Background Information
Interleukin-6 (IL-6) is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. IL-6 protein is secreted by a variety of cell types including T cells and macrophages as phosphorylated and variably glycosylated molecule. IL-6 plays an essential role in the final differentiation of B-cells into Ig-secreting cells involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. IL-6 is also considered a myokine, a cytokine produced from muscle, and is elevated in response to muscle contraction. IL-6 has been shown to interact with interleukin-6 receptor and glycoprotein 130. Additionally, IL-6 is involved in hematopoiesis, bone metabolism, and cancer progression, and has been defined an essential role in directing transition from innate to acquired immunity.
This antibody can be used to neutralize the bioactivity of IL-6.
Publications
What published studies show
| Species | Application | Title |
|---|---|---|
J Hepatol IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease | ||
J Exp Clin Cancer Res N-acetyl cysteine induces quiescent-like pancreatic stellate cells from an active state and attenuates cancer-stroma interactions. | ||
Int J Biol Sci Dual Phosphorylation of STAT1 at Y701/S727 by TNFα Drives AIM2-Mediated PANoptosis of Renal Tubular Epithelial Cells and Fibrotic Progression in Renal Allografts. | ||
Int J Biol Sci The RNF26/CBX7 axis modulates the TNF pathway to promote cell proliferation and regulate sensitivity to TKIs in ccRCC. | ||
Oncogene LncRNA XIST regulates breast cancer stem cells by activating proinflammatory IL-6/STAT3 signaling | ||
Cell Chem Biol Therapeutic potency of compound RMY-205 for pulmonary fibrosis induced by SARS-CoV-2 nucleocapsid protein |
